Atrial natriuretic peptide decreases cardiac output independent of coronary vasoconstriction

John C Jr. Burnett, G. M. Rubanyi, Brooks Sayre Edwards, T. R. Schwab, R. S. Zimmerman, P. M. Vanhoutte

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Studies were performed in isolated, Langendorff-perfused rat hearts and anesthetized dogs to determine the effects of synthetic atrial natriuretic peptide (ANP 8-33) on the coronary circulation. In vitro studies in the rat examined coronary flow dynamics to ANP 8-33 over a defined range from physiologic to pharmacologic concentrations. No changes in coronary flow or chronotropic and inotropic function of the isolated Langendorff-perfused heart were observed in response to increasing concentrations of ANP 8-33 (102 to 106 pg/ml). In the dog, a low, nonhypotensive dose of ANP 8-33 (0.05 μg/kg/min) decreased cardiac output with no change in coronary blood flow or coronary vascular resistance. At a high, hypotensive dose (0.3 μg/kg/min) ANP 8-33 decreased cardiac output in association with transient coronary vasodilation. Continued infusion resulted in a decrease in coronary blood flow and arterial pressure with no change in coronary vascular resistance. Thus, in vitro physiologic and pharmacologic concentrations of ANP, or in vivo low concentrations of ANP, do not result in an alteration in coronary flow. In vivo ANP 8-33, at both nonhypotensive and hypotensive concentrations, decreased cardiac output in the absence of coronary vasoconstriction.

Original languageEnglish (US)
Pages (from-to)313-318
Number of pages6
JournalProceedings of the Society for Experimental Biology and Medicine
Volume186
Issue number3
StatePublished - 1987

Fingerprint

Atrial Natriuretic Factor
Vasoconstriction
Cardiac Output
Vascular Resistance
Rats
Blood
Dogs
Coronary Circulation
Vasodilation
atrial natriuretic factor prohormone (8-33)
Arterial Pressure

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Atrial natriuretic peptide decreases cardiac output independent of coronary vasoconstriction. / Burnett, John C Jr.; Rubanyi, G. M.; Edwards, Brooks Sayre; Schwab, T. R.; Zimmerman, R. S.; Vanhoutte, P. M.

In: Proceedings of the Society for Experimental Biology and Medicine, Vol. 186, No. 3, 1987, p. 313-318.

Research output: Contribution to journalArticle

@article{82c160f0379a4752827ba5e45c10b46a,
title = "Atrial natriuretic peptide decreases cardiac output independent of coronary vasoconstriction",
abstract = "Studies were performed in isolated, Langendorff-perfused rat hearts and anesthetized dogs to determine the effects of synthetic atrial natriuretic peptide (ANP 8-33) on the coronary circulation. In vitro studies in the rat examined coronary flow dynamics to ANP 8-33 over a defined range from physiologic to pharmacologic concentrations. No changes in coronary flow or chronotropic and inotropic function of the isolated Langendorff-perfused heart were observed in response to increasing concentrations of ANP 8-33 (102 to 106 pg/ml). In the dog, a low, nonhypotensive dose of ANP 8-33 (0.05 μg/kg/min) decreased cardiac output with no change in coronary blood flow or coronary vascular resistance. At a high, hypotensive dose (0.3 μg/kg/min) ANP 8-33 decreased cardiac output in association with transient coronary vasodilation. Continued infusion resulted in a decrease in coronary blood flow and arterial pressure with no change in coronary vascular resistance. Thus, in vitro physiologic and pharmacologic concentrations of ANP, or in vivo low concentrations of ANP, do not result in an alteration in coronary flow. In vivo ANP 8-33, at both nonhypotensive and hypotensive concentrations, decreased cardiac output in the absence of coronary vasoconstriction.",
author = "Burnett, {John C Jr.} and Rubanyi, {G. M.} and Edwards, {Brooks Sayre} and Schwab, {T. R.} and Zimmerman, {R. S.} and Vanhoutte, {P. M.}",
year = "1987",
language = "English (US)",
volume = "186",
pages = "313--318",
journal = "Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)",
issn = "1535-3702",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Atrial natriuretic peptide decreases cardiac output independent of coronary vasoconstriction

AU - Burnett, John C Jr.

AU - Rubanyi, G. M.

AU - Edwards, Brooks Sayre

AU - Schwab, T. R.

AU - Zimmerman, R. S.

AU - Vanhoutte, P. M.

PY - 1987

Y1 - 1987

N2 - Studies were performed in isolated, Langendorff-perfused rat hearts and anesthetized dogs to determine the effects of synthetic atrial natriuretic peptide (ANP 8-33) on the coronary circulation. In vitro studies in the rat examined coronary flow dynamics to ANP 8-33 over a defined range from physiologic to pharmacologic concentrations. No changes in coronary flow or chronotropic and inotropic function of the isolated Langendorff-perfused heart were observed in response to increasing concentrations of ANP 8-33 (102 to 106 pg/ml). In the dog, a low, nonhypotensive dose of ANP 8-33 (0.05 μg/kg/min) decreased cardiac output with no change in coronary blood flow or coronary vascular resistance. At a high, hypotensive dose (0.3 μg/kg/min) ANP 8-33 decreased cardiac output in association with transient coronary vasodilation. Continued infusion resulted in a decrease in coronary blood flow and arterial pressure with no change in coronary vascular resistance. Thus, in vitro physiologic and pharmacologic concentrations of ANP, or in vivo low concentrations of ANP, do not result in an alteration in coronary flow. In vivo ANP 8-33, at both nonhypotensive and hypotensive concentrations, decreased cardiac output in the absence of coronary vasoconstriction.

AB - Studies were performed in isolated, Langendorff-perfused rat hearts and anesthetized dogs to determine the effects of synthetic atrial natriuretic peptide (ANP 8-33) on the coronary circulation. In vitro studies in the rat examined coronary flow dynamics to ANP 8-33 over a defined range from physiologic to pharmacologic concentrations. No changes in coronary flow or chronotropic and inotropic function of the isolated Langendorff-perfused heart were observed in response to increasing concentrations of ANP 8-33 (102 to 106 pg/ml). In the dog, a low, nonhypotensive dose of ANP 8-33 (0.05 μg/kg/min) decreased cardiac output with no change in coronary blood flow or coronary vascular resistance. At a high, hypotensive dose (0.3 μg/kg/min) ANP 8-33 decreased cardiac output in association with transient coronary vasodilation. Continued infusion resulted in a decrease in coronary blood flow and arterial pressure with no change in coronary vascular resistance. Thus, in vitro physiologic and pharmacologic concentrations of ANP, or in vivo low concentrations of ANP, do not result in an alteration in coronary flow. In vivo ANP 8-33, at both nonhypotensive and hypotensive concentrations, decreased cardiac output in the absence of coronary vasoconstriction.

UR - http://www.scopus.com/inward/record.url?scp=0023571372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023571372&partnerID=8YFLogxK

M3 - Article

C2 - 2962199

AN - SCOPUS:0023571372

VL - 186

SP - 313

EP - 318

JO - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

JF - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

SN - 1535-3702

IS - 3

ER -